Back to top

Amgen Extends MariTide Study In Obesity And Diabetes, Keeping Investor Focus On Long-Term Potential

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. is moving ahead with MARITIME-2-EXTENSION, a Phase 3 trial that t...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Amgen Inc. (AMGN)